AU2020338043B2 — Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
Assigned to Chemwerth Inc · Expires 2025-12-18 · 0y expired
What this patent protects
The disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula (I) The variables, R, R!-R3 and the A-ring are described herein. A can be a cyclohexyl ring. The compounds are inhibitors of JAK1 Kinase and are useful in methods of treating an allergic, i…
USPTO Abstract
The disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula (I) The variables, R, R!-R3 and the A-ring are described herein. A can be a cyclohexyl ring. The compounds are inhibitors of JAK1 Kinase and are useful in methods of treating an allergic, inflammatory, or autoimmune disorders, in a patient, comprising administering a therapeutically effective amount of compound of Formula I or salt thereof, to the patient. The disclosure also provides pharmaceutical formulations containing a compound of Formula I.
Drugs covered by this patent
- Litfulo (Ritlecitinib Tosylate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.